Keros Therapeutics

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with hematological, pulmonary and musculoskeletal disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. Their science focuses on the complex TGF-β superfamily, which plays critical roles in tissue development and homeostasis, and they have developed a pipeline of product candidates aimed at treating diseases associated with imbalanced TGF-β signaling.

Their current pipeline includes KER-050, a therapeutic protein designed to inhibit select TGF-β ligands and potentially treat myelodysplastic syndromes and myelofibrosis; KER-012, an investigational fusion protein being developed for the treatment of pulmonary arterial hypertension and other cardiovascular disorders; and KER-065, a selective activin receptor ligand trap being developed for the treatment of obesity and neuromuscular disorders. Keros is committed to delivering significant clinical benefit to patients with diseases of high unmet medical need.

Keros Therapeutics offers flexible work schedule options as a benefit to its employees. They also have an open door policy and encourage a collaborative and inclusive culture, which likely translates to a comfortable and flexible work environment.

Keros Therapeutics offers a comprehensive benefits package designed to support employee well-being and financial security. This includes generous paid time off, competitive 401k matching, life and disability insurance at no cost, identity theft protection, medical, dental, and vision insurance, pet insurance, tuition reimbursement, and a collaborative and inclusive work environment with flexible work schedule options and an open-door policy. They also encourage and support career development opportunities at all levels of the organization.

Keros Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies that modulate the transforming growth factor-beta (TGF-β) signaling pathway to address a wide range of diseases with high unmet medical need. Their mission is to create treatments that have the potential to significantly improve the lives of patients suffering from hematological, pulmonary, and musculoskeletal disorders by addressing the underlying disease pathology and potentially offering disease-modifying benefits.

Keros Therapeutics promotes a collaborative and inclusive culture that values diversity, encourages open communication, and prioritizes employee development. They offer a flexible work schedule, open door policy, and tuition reimbursement, fostering a supportive and engaging environment where employees feel valued and empowered to achieve their full potential.

Keros Therapeutics is committed to fostering a diverse and inclusive workplace where all voices are heard and valued. They believe that a diverse workforce drives innovation and fosters a collaborative and respectful environment. Keros takes a holistic approach to mentorship, coaching, and development for all team members, encouraging growth opportunities at all levels of the organization.